US2005267189A1PendingUtilityA1

Celecoxib compositions

43
Assignee: G D SEARLE L L CPriority: Nov 30, 1998Filed: Feb 11, 2004Published: Dec 1, 2005
Est. expiryNov 30, 2018(expired)· nominal 20-yr term from priority
Inventors:Danchen GaoAnthony J. HlinakAhmad M. MazharyJames E. TrueloveMargaret V. Vaughn
A61P 37/08A61P 35/00A61P 31/18A61P 7/04A61P 37/00A61P 3/10A61P 9/10A61P 7/06A61P 9/00A61P 43/00A61P 37/06A61P 25/04A61P 25/06A61P 29/00A61P 25/28A61P 27/14A61P 25/00A61P 27/06A61P 27/02A61P 19/02A61P 19/08A61P 1/04A61P 1/00A61P 17/04A61P 17/00A61P 17/10A61P 17/16A61P 19/10A61P 11/00A61P 21/04A61P 17/06A61P 11/06A61P 15/00A61P 13/12A61P 17/02A61P 19/04A61P 1/16A61K 9/2018A61K 9/2027A61K 9/4866A61K 9/2054A61K 31/635A61K 9/0053A61K 9/4858A61K 9/1694A61K 31/415A61K 9/2013A61K 9/2095A61K 45/06
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising one or more orally deliverable dose units, each comprising a blend of particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with at least one excipient.  
     
     
         2 . The composition of  claim 1  wherein the excipient comprises at least one member selected the group consisting of a diluent, a disintegrant, a binding agent, a wetting agent, and a lubricant.  
     
     
         3 . The composition of  claim 1  wherein the excipient comprises at least one member selected from the group consisting of a water soluble diluent and a wetting agent.  
     
     
         4 . The composition of  claim 1  wherein the excipient comprises at least one member selected from the group consisting of: 
 a) a diluent in an amount of about 5 to about 99 percent by weight of the total weight of the dose unit,    b) a disintegrant in an amount of about 0.5 to about 30 percent by weight of the total weight of the dose unit, and    c) a binding agent in an amount of about 0.5 to about 25 percent by weight of the total weight of the dose unit,    and wherein the celecoxib is in an amount of about 1 to about 95 percent by weight of the total weight of the dose unit.    
     
     
         5 . The composition of  claim 1  wherein the excipient comprises: 
 (e) lactose in an amount of about 30 to about 225 mg per dose unit,    (f) croscarmellose sodium in an amount of about 0.5 to about 25 mg per dose unit, and    (g) polyvinylpyrrolidone in an amount of about 0.5 to about 25 mg per dose unit,    and wherein the celecoxib is in an amount about 80 to about 220 mg.    
     
     
         6 . The composition of  claim 5  further comprising at least one excipient selected from the group consisting sodium lauryl sulfate in an amount of about 0.5 to about 25 mg per dose unit, magnesium stearate in an amount of about 0.2 to about 10 mg per dose unit, and microcrystalline cellulose in an amount of about 1 mg to about 70 mg per dose unit.  
     
     
         7 . The composition of  claim 1  produced by a process comprising pin milling.  
     
     
         8 . The composition of  claim 1  produced by a process comprising wet granulation.  
     
     
         9 . The composition of  claim 1  produced by a process comprising pin milling and wet granulation.

Join the waitlist — get patent alerts

Track US2005267189A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.